Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2007

Li Hongtao, Dutuor Aurelie, Tao Lihua, Fu Xinping, Zhang Xiaoliu

Abstract excerpt

PURPOSE: We recently constructed an oncolytic virus from type 2 herpes simplex virus (HSV-2) that selectively targets and kills tumor cells with an activated Ras signaling pathway. Designated FusOn-H2, this virus has shown several discrete killing mechanisms. Here, we evaluated the antitumor immune responses after FusOn-H2-mediated virotherapy in a syngeneic murine neuroblastoma model. EXPERIMENTAL DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus 2, Human
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to Neuroblastoma

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Vero Cells

Source

Identifiers

PMID: 17200370
DOI: 10.1158/1078-0432.CCR-06-1625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.PMID 17200370Read ↗

Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.Semantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

Viral oncolysis by herpes simplex virus and other viruses.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1Semantic proximity Read ↗

Active immunotherapy: oncolytic virus therapy using HSV-1.Semantic proximity Read ↗

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Semantic proximity Read ↗

Replicative oncolytic herpes simplex viruses in combination cancer therapies.Semantic proximity Read ↗

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.